ASSEMBLY BIOSCIENCES, INC. IR

interim report · 2025-06-30

The Safety and Pharmacokinetics of ABI-4334, a Novel Next-Generation HBV Core Inhibitor: Interim Results From a Phase 1 Study in Healthy Volunteers